TerminatedPhase 4

Fentanyl and Crushed Ticagrelor in Percutaneous Coronary Intervention

Stopped: Researcher stopped study due to slow accrual rate

United States45 participantsStarted 2018-04-18

Plain-language summary

During a percutaneous coronary intervention (PCI), Fentanyl is commonly used for sedation. Ticagrelor is also routinely used as anti-platelet agent during PCI. However, a recent study has demonstrated the decrease in effectiveness of Ticagrelor when administered along with Fentanyl. Hence this study was designed to further assess the interaction between crushed vs non crushed Ticagrelor and Fentanyl given during PCI procedures.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Undergoing clinically indicated elective or non-elective PCI * Able to swallow oral medications Exclusion Criteria: * Contraindications to ticagrelor or fentanyl (or other opiates) * Pregnancy * Any use of P2Y12 inhibitors within 14 days * Known coagulation disorders * Pre-procedural treatment with an anticoagulant (oral anticoagulant or low molecular weight heparin) * Platelet count \< 100,000/mm3 * Impaired renal function (Estimated glomerular filtration \< 45 ml/min/1.73 m2) * Impaired hepatic function (Based on medical history) * Prior or planned transcatheter aortic valve replacement

What they're measuring

Area Under the Platelet Function Testing (PFT)-Time Curve (AUC0-6) for the First 6 Hours After the Loading Dose of Ticagrelor

Timeframe: 6 hours after the loading dose of Ticagrelor

Trial details

NCT IDNCT03476369

SponsorThe Guthrie Clinic

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-01-23

Results submitted2025-12-30

View on ClinicalTrials.gov More Percutaneous Coronary Intervention trials